Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design
about
Spinal muscular atrophySpinal muscular atrophy: from gene discovery to clinical trialsApplicability of histone deacetylase inhibition for the treatment of spinal muscular atrophyAssays for the identification and prioritization of drug candidates for spinal muscular atrophyNew therapeutic approaches to spinal muscular atrophy.Therapeutic strategies for the treatment of spinal muscular atrophy.SMN-inducing compounds for the treatment of spinal muscular atrophy.Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein.Therapy development for spinal muscular atrophy in SMN independent targets.Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA)A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy ControlsRecent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker studyBeta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes.Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults.Biomarkers in rare disorders: the experience with spinal muscular atrophy.Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects.Investigational therapies for the treatment of spinal muscular atrophy.Therapeutic approaches for spinal muscular atrophy (SMA).Perceived efficacy of salbutamol by persons with spinal muscular atrophy: A mixed methods study.Muscle magnetic resonance imaging in spinal muscular atrophy type 3: Selective and progressive involvement.Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophySalbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells.Solving the puzzle of spinal muscular atrophy: what are the missing pieces?
P2860
Q21202863-30D4D5C7-8563-4A20-8CAF-EDCC6D0A11EDQ26824894-4B3A99BC-29D6-4558-B24B-22D02C2885FAQ26864605-F8A6E578-E821-4C8C-85DB-5E22CB3FB299Q34082155-B5B3F666-1AB7-464C-8141-E9C68F3BAC20Q34237525-77B20984-3834-4533-B4D4-4FB97AAC20F8Q34296140-E686B8FE-1EF1-4861-8D1D-E0090EF38B37Q34312156-A0A6E0F0-FB89-4D4A-B03B-AB0488583920Q34505876-A07D10B1-4795-4421-B394-BEB50ABF0849Q36014761-EA1F1D95-BA39-44A9-A6D3-AEF1DA0F34A5Q36184477-309FDD76-87B1-43E7-BE7E-5E7893784927Q36205773-EB03E97F-E32E-4A3B-835D-C55D111485D4Q36761839-1ADC7ADD-048F-4825-A0C2-E4F4C419C025Q36856405-13577E4B-0CF3-4BDD-BE70-ADBEEC80C119Q37602169-575BCFB6-178A-4CF4-A724-39C71E758787Q37610527-EAC467DC-E42E-4B47-8B9C-F7FE0BD5E2D5Q37845667-3BB218B7-BB6C-40C9-9B81-F3F81E77CA68Q38014955-04A141E5-CB4F-486A-9543-D671FF3614C4Q38441280-C7B5D83F-08DF-48EF-B6D6-DBFD306CB768Q39340546-1BC862B8-CCDF-4891-AC0C-83BD05DD766CQ39926048-57EEDC90-10C4-4E23-8BCA-BDD38C867654Q40614216-9E5C5DB2-20B0-462C-892B-EA88634BA86CQ41683448-30AF7E2C-F36A-4705-8D5B-BB81484C06AAQ43271983-103D5020-8905-49E5-88EB-87B32704D51AQ54765007-900B60E9-E45C-4979-897D-C5C232D1C3BB
P2860
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Salbutamol increases survival ...... ance for clinical trial design
@ast
Salbutamol increases survival ...... ance for clinical trial design
@en
Salbutamol increases survival ...... ance for clinical trial design
@nl
type
label
Salbutamol increases survival ...... ance for clinical trial design
@ast
Salbutamol increases survival ...... ance for clinical trial design
@en
Salbutamol increases survival ...... ance for clinical trial design
@nl
prefLabel
Salbutamol increases survival ...... ance for clinical trial design
@ast
Salbutamol increases survival ...... ance for clinical trial design
@en
Salbutamol increases survival ...... ance for clinical trial design
@nl
P2093
P50
P3181
P356
P1476
Salbutamol increases survival ...... ance for clinical trial design
@en
P2093
Carla Angelozzi
Christina Brahe
Francesco Danilo Tiziano
Giovanni Neri
Marika Pane
Rosa Lomastro
Stefania Fiori
P3181
P356
10.1136/JMG.2010.080366
P407
P577
2010-12-01T00:00:00Z